Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind …
…, RM Herd, R Kudchadkar, U Trefzer, S Gogov… - The Lancet …, 2015 - thelancet.com
Background Patients with advanced basal cell carcinoma have limited treatment options.
Hedgehog pathway signalling is aberrantly activated in around 95% of tumours. We assessed …
Hedgehog pathway signalling is aberrantly activated in around 95% of tumours. We assessed …
[PDF][PDF] Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non–small-cell lung cancer
…, F Barlesi, P Langmuir, S Gogov… - Journal of Clinical …, 2011 - researchgate.net
Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor
and epidermal growth factor receptor signaling. This phase III study assessed the efficacy …
and epidermal growth factor receptor signaling. This phase III study assessed the efficacy …
Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review
SMH Alibhai, S Gogov, Z Allibhai - Critical reviews in oncology/hematology, 2006 - Elsevier
Increasing numbers of men with non-metastatic disease are receiving androgen deprivation
therapy (ADT) for a variety of indications, some of which are supported by evidence from …
therapy (ADT) for a variety of indications, some of which are supported by evidence from …
[HTML][HTML] The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in …
…, AJ Stratigos, HJ Schulze, R Plummer, S Gogov… - Journal of the American …, 2016 - Elsevier
Background The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor
shrinkage in more than 90% of patients with locally advanced basal cell carcinoma (BCC) or …
shrinkage in more than 90% of patients with locally advanced basal cell carcinoma (BCC) or …
Low-intensity laser therapy for painful symptoms of diabetic sensorimotor polyneuropathy: a controlled trial
LH Zinman, M Ngo, ET Ng, KT Nwe, S Gogov… - Diabetes …, 2004 - Am Diabetes Assoc
OBJECTIVE—Low-intensity laser therapy (LILT) has been advocated for treatment of chronic
pain disorders. Although the mechanism of pain relief is uncertain, this therapy has been …
pain disorders. Although the mechanism of pain relief is uncertain, this therapy has been …
Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in …
…, JT Beck, PM Patel, E Schiff, A Vaury, J Niolat, S Gogov… - 2013 - ascopubs.org
4504 Background: Sequential SUN (tyrosine kinase inhibitor, TKI) until progression of disease
(PD) followed by EVE (mTOR inhibitor) is standard therapy for patients with mRCC. This …
(PD) followed by EVE (mTOR inhibitor) is standard therapy for patients with mRCC. This …
Phase I dose-escalation study of linsitinib (OSI-906) and erlotinib in patients with advanced solid tumors
…, CM Rudin, RA Juergens, R Gedrich, S Gogov… - Clinical Cancer …, 2016 - AACR
Purpose: Cross-talk between type I IGF receptor (IGF1R), insulin receptor (INSR), and epidermal
growth factor receptor (EGFR) mediates resistance to individual receptor blockade. This …
growth factor receptor (EGFR) mediates resistance to individual receptor blockade. This …
Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors
…, J Zhou, O Chiparus, PH Huang, S Gogov… - Cancer chemotherapy …, 2016 - Springer
Purpose Sonidegib (Odomzo) selectively inhibits smoothened and suppresses the growth
of hedgehog pathway-dependent tumors. A population pharmacokinetic (PK) analysis of …
of hedgehog pathway-dependent tumors. A population pharmacokinetic (PK) analysis of …
[HTML][HTML] Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine …
…, Z Ye, H Wang, A Jappe, P Straub, N Pirotta, S Gogov - BMC cancer, 2013 - Springer
Background In China, there are currently no approved therapies for the treatment of metastatic
renal cell carcinoma (mRCC) following progression with vascular endothelial growth …
renal cell carcinoma (mRCC) following progression with vascular endothelial growth …
A phase I/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients (Pts) with advanced biliary tract cancers.
…, JLR Canon, L Cheng, S Ioannidis, S Gogov… - 2021 - ascopubs.org
311 Background: Arginase, secreted in the tumor microenvironment by myeloid suppressor
cells, is a major regulator of arginine-mediated immune response. Arginase inhibition by …
cells, is a major regulator of arginine-mediated immune response. Arginase inhibition by …
